Akorn Inc. received a warning letter from the U.S. Food and Drug Administration regarding a manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker, sending the company’s shares down nearly 13 percent.
Contract research organization Catalent plans to buy Bristol-Myers Squibb’s manufacturing and packaging factory in Anagni, Italy, used to manufacture oral solid, biologics and sterile products.
With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.
Merck & Co. filed with the U.S. Securities and Exchange Commission that the company plans an extensive restructuring of its manufacturing and supply network.
Lilly inked a deal with Eddingpharm for the rights to two legacy antibiotic medicines and a manufacturing facility in Suzhou, China.
U.S. drugmaker Pfizer Inc. said the company was shutting down two manufacturing plants in India that make generic injectables such as penicillin in response to falling demand.
Akorn Inc. received a warning letter from the U.S. Food and Drug Administration following an inspection of the generic drugmaker’s Decatur, Illinois manufacturing plant during 2018.
South San Francisco-based Genentech filed with the State of California, indicating that the Roche company planned to cut 83 jobs.
Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately held companies in the region with an earnings increase of more than 2,000 percent over a three-year period. As a result of that growth, the company optioned space in its town of Pleasanton, Calif.
German company Bayer AG is laying off 227 staffers at the company’s manufacturing plant in Berkeley, California. Most of the cuts took place on October 3, 2018.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!
